Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza vaccine (2016-2017 formulation)
- Development stage
- Approved
- Lead developer
- World Health Organization
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
The 2016-2017 influenza vaccine is a seasonal vaccine designed to protect against influenza viruses predicted to be most common during the 2016-2017 flu season. The vaccine was available in both trivalent and quadrivalent formulations. The trivalent vaccines contained antigens from three influenza strains: an A/California/7/2009 (H1N1)–like virus, an A/Hong Kong/4801/2014 (H3N2)–like virus, and a B/Brisbane/60/2008–like virus (Victoria lineage). The quadrivalent vaccines contained the same three antigens plus a B/Phuket/3073/2013–like virus (Yamagata lineage). The composition for 2016-17 represented a change in the influenza A(H3N2) virus and a switch in lineage for the influenza B viruses compared to previous seasons. The vaccine was available in various formulations including standard-dose inactivated, high-dose inactivated, cell culture-based, recombinant, adjuvanted, and live attenuated versions.
- Brand names
- AfluriaFluadFluarixFlublokFlucelvax QuadrivalentFluLavalFlumist QuadrivalentFluvirinFluzoneFluzone High-Dose
- Other names
- Flu shotFlu vaccine
02
Targets
T-cell receptor recognizing influenza peptide–major histocompatibility complexBCR (Immunoglobulin G B Cell Receptor)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Influenza vaccine (2016-2017 formulation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza vaccine (2016-2017 formulation).